An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
About this item
Full title
Author / Creator
Type 1 Diabetes TrialNet Study Group , Herold, Kevan C , Bundy, Brian N , Long, S. Alice , Bluestone, Jeffrey A , DiMeglio, Linda A , Dufort, Matthew J , Gitelman, Stephen E , Gottlieb, Peter A , Krischer, Jeffrey P , Linsley, Peter S , Marks, Jennifer B , Moore, Wayne , Moran, Antoinette , Rodriguez, Henry , Russell, William E , Schatz, Desmond , Skyler, Jay S , Tsalikian, Eva , Wherrett, Diane K , Ziegler, Anette-Gabriele and Greenbaum, Carla J
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this trial, high-risk nondiabetic relatives of patients with type 1 diabetes were randomly assigned to receive teplizumab (an anti-CD3 monoclonal antibody) or placebo and were followed for type 1 diabetes. Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants.
Alternative Titles
Full title
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Authors, Artists and Contributors
Author / Creator
Herold, Kevan C
Bundy, Brian N
Long, S. Alice
Bluestone, Jeffrey A
DiMeglio, Linda A
Dufort, Matthew J
Gitelman, Stephen E
Gottlieb, Peter A
Krischer, Jeffrey P
Linsley, Peter S
Marks, Jennifer B
Moore, Wayne
Moran, Antoinette
Rodriguez, Henry
Russell, William E
Schatz, Desmond
Skyler, Jay S
Tsalikian, Eva
Wherrett, Diane K
Ziegler, Anette-Gabriele
Greenbaum, Carla J
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6776880
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6776880
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1902226
